Anti-Norovirus, Capsid (Clone NORO-178)-Purified No Carrier Protein

Specificity: NORO-178 targets the capsid of a broad range of Norovirus genotypes, including GII.
Antigen Distribution: Norovirus infects and replicates in immune cells, including macrophages, dendritic cells, and B cells, as well as in enteroendocrine cells in the human gut.
Background:Norovirus is a highly contagious pathogen known for its ability to cause acute gastroenteritis, which is a major health concern worldwide1. The virus's low infectious dose means minor exposure can lead to infection. Prolonged shedding by hosts and environmental resilience further heighten transmission risks through prolonged surface contamination2. It is the leading cause of foodborne diseases, exclusively infecting humans3. Timely implementation of infection prevention measures is crucial for outbreak control2. Studies have found a variety of antibodies that have a broad reactivity for noroviruses, including single-chain antibodies4, monoclonal antibodies5, and a cross-reactive monoclonal antibody6. These antibodies have the potential to be used in diagnostic applications as they have been shown to detect norovirus antigens in clinical samples. Studies have also found that the reactivity of these antibodies can vary depending on the norovirus strain7. NORO-178 is a monoclonal antibody with broad effectiveness against Norwalk virus genogroup II (GII), notably neutralizing various GII genotypes by blocking their interaction with human histo-blood group antigens (HBGAs). Its fragment antigen-binding (Fab) version is even more effective against GII.4 strains but doesn't block HBGA binding, suggesting NORO-178 neutralizes the virus by physically obstructing its attachment to host cells. This is likely due to the antibody's targeting of a universally conserved area within the viral capsid P-domain, underscoring NORO-178's potential in therapeutic applications against norovirus infections8.